Lupin Ltd

Nanomi B.V., a Dutch subsidiary of the global pharma major Lupin, today announced that it has won the prestigious CMO Award for Life Science Leadership in Drug Delivery, during the Drug, Chemical and Associated Technologies Association (DCAT) week at New York. Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare.Powered by Capital Market - Live

Lupin has allotted 24,101 equity shares under ESOP on 21 March 2025. In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,31,30,090 consisting of 45,65,65,045 equity shares of Rs 2/- each.Powered by Capital Market - Live

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg. This product would be manufactured at Lupin's Goa facility in India. Amifampridine Tablets, 10 mg, are bioequivalent to Firdapse' Tablets, 10 mg of Catalyst Pharmaceuticals, Inc., and are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older. Amifampridine Tablets, 10 mg (RLD Firdapse') had an estimated global net sale of USD 306 million for the fiscal year ended December 31, 2024.Powered by Capital Market - Live

Amifampridine Tablets, 10 mg, are bioequivalent to Firdapse Tablets, 10 mg, from Catalyst Pharmaceuticals, Inc., and are indicated for the treatment of Lambert-Eaton Myasthenic Syndrome in adults and pediatric patients 6 years of age and older. This product will be manufactured at Lupin's Goa facility in India. Amifampridine Tablets, 10 mg (RLD Firdapse), had an estimated global net sale of $306 million for the fiscal year ended 31 December 2024. Mumbai-based Lupin is an innovation-led, transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupin's consolidated net profit jumped 38.81% to Rs 858.86 crore on a 10.60% increase in sales to Rs 5,618.6 crore in Q3 FY25 compared to Q3 FY24.Powered by Capital Market - Live

The newly launched drug is bioequivalent to Xarelto 2.5 mg from Janssen Pharmaceuticals, Inc. Rivaroxaban is indicated for reducing the risk of major cardiovascular events in patients with coronary artery disease (CAD) and major thrombotic vascular events in patients with peripheral artery disease (PAD), including those who have undergone lower extremity revascularization due to symptomatic PAD. According to IQVIA MAT data for January 2025, rivaroxaban tablets USP, 2.5 mg, had estimated annual sales of $446 million in the US. Mumbai-based Lupin is an innovation-led, transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupin's consolidated net profit jumped 38.81% to Rs 858.86 crore on a 10.60% increase in sales to Rs 5,618.6 crore in Q3 FY25 compared to Q3 FY24. Shares of Lupin rose 0.69% to Rs 2,043 on the BSE.Powered by Capital Market - Live

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA. Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto' Tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated: ' to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ' to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD. Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto') had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025). Powered by Capital Market - Live

Lupin Ltd gained for a fifth straight session today. The stock is quoting at Rs 2022, up 0.59% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 22447.2. The Sensex is at 74002.94, up 0.37%. Lupin Ltd has slipped around 8.14% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has slipped around 7.63% in last one month and is currently quoting at 20126.8, up 1.33% on the day. The volume in the stock stood at 2.87 lakh shares today, compared to the daily average of 11.26 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 2032.95, up 0.6% on the day. Lupin Ltd is up 21.1% in last one year as compared to a 0.21% drop in NIFTY and a 6.25% drop in the Nifty Pharma index.The PE of the stock is 29.33 based on TTM earnings ending December 24.Powered by Capital Market - Live

Lupin has allotted 59,940 equity shares under ESOP on 27 February 2025. In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,30,81,888 consisting of 45,65,40,944 equity shares of Rs 2/- each.Powered by Capital Market - Live

The USFDA inspected the facility from 27th January 2025 to 31st January 2025. Nilesh Gupta, managing director, Lupin, said, 'We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupin's consolidated net profit jumped 38.81% to Rs 858.86 crore on 10.60% increase in sales to Rs 5,618.6 crore in Q3 FY25 over Q3 FY24. The counter declined 3.61% to end at Rs 1906.15 on Friday, 21 February 2025Powered by Capital Market - Live

Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from 27 January to 31 January 2025. 'We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer,' said Nilesh Gupta, Managing Director, Lupin. Powered by Capital Market - Live